Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Cabaret Biotech Files Lawsuit Against Gilead Over Yescarta Drug

Sept. 16, 2019, 8:45 PM

Closely held Cabaret Biotech said it had filed a preemptive lawsuit against Gilead Sciences Inc. and its Kite unit “to end a needless dispute about patent royalties” over the cancer treatment Yescarta.

  • Gilead, which exclusively licenses a patent from Cabaret for Yescarta in the field of oncology, has protested its royalty payment obligations since October 2018, according to complaint filed Monday in federal court in Wilmington, Delaware
  • Cabaret is seeking a judgment that the patent isn’t invalid and that but for the license agreement, Yescarta infringes the patent, complaint says
  • Kite paid licensing fees, royalties and milestone payments to Cabaret ...